Real-world Effectiveness and Safety Study of T-Dxd in Chinese Metastatic Breast Cancer

A Trial Comparing Docetaxel Plus Fulvestrant With Docetaxel in Metastatic Breast Cancer

NCT02137083 ·Status: COMPLETED ·Phase: PHASE2

Trastuzumab Deruxtecan in Advanced Breast Cancer

NCT07180264 ·Status: RECRUITING

T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis

NCT07152782 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

A Real-world Clinical Study of T-DXd for the Treatment of Chinese Patients With HER2 Overexpressing and HER2 Underexpressing Advanced Breast Cancer

NCT07035353 ·Status: NOT_YET_RECRUITING

Trastuzumab Deruxtecan (T-DXd) With Pyrotinib in First-line HER2-positive Unresectable or Metastatic Breast Cancer Trial

NCT06245824 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4

Trastuzumab Plus Taxane Neoadjuvant Therapy for HER2-Positive Breast Ductal Carcinoma In Situ (DCIS) : A Phase II Study

NCT06843681 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE2

Initial CDK 4/6 Inhibitor Plus Endocrine Therapy Versus Initial Chemotherapy in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer

NCT06344793 ·Status: COMPLETED

Short-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer

NCT05891561 ·Status: RECRUITING ·Phase: PHASE2

Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd

NCT07073755 ·Status: RECRUITING

T-DXd Versus THP for Medium-risk HER2-positive Early Breast Cancer

NCT06548178 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

A Phase II Study to Evaluate the Efficacy and Safety of Anti-HER2 Triple-targeted Drugs Combined With CDK4/6 Inhibitors in Neoadjuvant Therapy for ER-positive HER2-positive Breast Cancer Patients.

NCT07290166 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

A Clinical Trial of Breast Cancer Neo-adjuvant Therapy Based on Molecular Pathway in FUSCC

NCT04215003 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

NCT04494425 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.

NCT05411380 ·Status: UNKNOWN ·Phase: PHASE2

Real-world Study on the Management of Hematological Toxicities Associated With Targeted Therapies for Breast Cancer

NCT06503380 ·Status: RECRUITING

A Study to Assess the Efficiency of Trastuzumab Deruxtecan in Russian Breast Cancer Patients

NCT07281001 ·Status: RECRUITING ·Phase: NA

A Study to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer

NCT02896855 ·Status: COMPLETED ·Phase: PHASE3

A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel in Patients With HER2-positive Breast Cancer

NCT02144012 ·Status: TERMINATED ·Phase: PHASE3

A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Participants With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment

NCT01301729 ·Status: COMPLETED ·Phase: PHASE4

A Study Evaluating the Efficacy and Safety of De Trastuzumab (T-DXd) in Combination with Immunotherapy for the Neoadjuvant Treatment of HR-positive HER2 Low-expressing Chinese Patients with Early-stage Breast Cancer

NCT06733233 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Trastuzumab Rezetecan Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

NCT07047755 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy

NCT06680596 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE2

ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd

NCT06578286 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Targeted Next Generation Sequencing for the Efficacy of Trastuzumab Neoadjuvant Chemotherapy in Breast Cancer

NCT03728829 ·Status: UNKNOWN

Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer

NCT04481932 ·Status: RECRUITING ·Phase: PHASE2